Asset profile
AD-209
Small molecule
Evidence outlook · registrational
Hypertension: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. The registry's posted readout date (2025-02) has passed without a status update. Check News for topline announcements.
NCT05631990: The trial was randomized, double-blind, and placebo-controlled, with 221 participants, and used change in mean sitting systolic blood pressure as its primary clinical endpoint. Because the registry provides no results, it is not possible to determine whether the primary endpoint was met.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 8 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AD-209: this drug | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporter | ||
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Epoprostenol (Flolan) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| Nitric Oxide (INOmax) | Approved | Gas (inhaled) | Nitric oxide | ||
| Sacubitril / Valsartan (Entresto) | Approved | Small molecule | Neprilysin + Angiotensin II receptor (dual) | ||
| Treprostinil (Orenitram / Remodulin / Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| AGSAVI | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | ||
| AJU-C52 | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | ||
| Ambrisentan (Letairis) | Phase 3 | Small molecule | Endothelin A receptor | ||
| C2402 | Phase 3 | Small molecule | — | ||
| CJ-30060 | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | ||
| CJ-30061 | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | ||
| DWC202206 + DWC202207 | Phase 3 | Small molecule | — |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.